Castellum (NYSEAMERICAN:CTM – Get Free Report) was upgraded by investment analysts at Maxim Group to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.
Castellum Stock Up 1.3 %
Shares of CTM opened at $1.01 on Thursday. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average price of $1.03 and a two-hundred day moving average price of $0.67. The stock has a market cap of $70.64 million, a price-to-earnings ratio of -5.94 and a beta of -12.75. Castellum has a 12 month low of $0.12 and a 12 month high of $2.83.
Insider Activity at Castellum
In other Castellum news, Director Mark C. Fuller sold 275,000 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $1.49, for a total transaction of $409,750.00. Following the sale, the director now directly owns 7,338,659 shares of the company’s stock, valued at approximately $10,934,601.91. This represents a 3.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 45.55% of the stock is owned by insiders.
Institutional Inflows and Outflows
About Castellum
Castellum, Inc provides services in the areas of cybersecurity, information technology, electronic and information warfare, and information operations. Its services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model based systems engineering services.
Featured Stories
- Five stocks we like better than Castellum
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Short Sellers Gave Up on These 3 Names Recently
- How to Calculate Inflation Rate
- 3 Boring Stocks Outperforming the Market This Year
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Receive News & Ratings for Castellum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castellum and related companies with MarketBeat.com's FREE daily email newsletter.